Direxion Daily Pharmaceutical & Medical Bull 2X Shares PILL 深 沪
等待开盘 04-01 09:30:00 美东时间
10.22
+1.300
+14.57%
华盛通- 最 高10.27
- 今 开9.14
- 成交量 10.10万股
- 最 低 9.14
- 昨 收 8.92
- 总市值 1277.50万
- 52周最高 13.6591
- 市盈率 静 --
- 换手率 8.08%
- 52周最低 4.1022
- 委 比 0.00%
- 总股本 125.00万
- 历史最高 42.2213
- 量 比 1.30
- 振 幅 12.67%
- 历史最低 3.5422
- 每 手 1
- 风险率 2.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股夜盘 | Direxion Daily Pharmaceutical & Medical Bull 2X Shares涨10.54%，最新股价10.17美元
Direxion Daily Pharmaceutical & Medical Bull 2X Shares涨10.54%，报10.17美元
03-30 13:24
BRIEF-J&J Says Icotyde One-Year Results Confirm Lasting Skin Clearance And Favorable Safety Profile In Once‑Daily Pill For Plaque Psoriasis
BRIEF-J&J Says Icotyde One-Year Results Confirm Lasting Skin Clearance And Favorable Safety Profile In Once‑Daily Pill For Plaque Psoriasis March 28 (Reuters) - Johnson & Johnson JNJ.N : J&J: ICOTYDE™ (ICOTROKINRA) ONE-YEAR RESULTS CONFIRM LASTING SKIN CLEARANCE AND FAVORABLE SAFETY PROFILE IN ONCE
03-28 22:03
BRIEF-Hims & Hers Says We Will Expand Our Platform To Include Wegovy® Pills And Injections And Ozempic® Injections
BRIEF-Hims & Hers Says We Will Expand Our Platform To Include Wegovy® Pills And Injections And Ozempic® Injections March 18 (Reuters) - Hims & Hers Health Inc HIMS.N : HIMS & HERS: WE WILL EXPAND OUR PLATFORM TO INCLUDE WEGOVY® PILLS AND INJECTIONS AND OZEMPIC® INJECTIONS HIMS & HERS HEALTH INC - WE
03-18 20:51
BRIEF-Atlas Energy Solutions Enters Agreement With Caterpillar To Secure Power Generation Assets Through 2029
BRIEF-Atlas Energy Solutions Enters Agreement With Caterpillar To Secure Power Generation Assets Through 2029 March 10 (Reuters) - Atlas Energy Solutions Inc AESI.N : ATLAS ENERGY SOLUTIONS ENTERS AGREEMENT WITH CATERPILLAR INC. TO SECURE POWER GENERATION ASSETS THROUGH 2029 TO SUPPORT PRIVATE GRID
03-10 19:05
BRIEF-Caterpillar Elevates Skilled Trades Through Global Technician And Operator Challenges
BRIEF-Caterpillar Elevates Skilled Trades Through Global Technician And Operator Challenges March 4 (Reuters) - Caterpillar Inc CAT.N : CATERPILLAR ELEVATES SKILLED TRADES THROUGH GLOBAL TECHNICIAN AND OPERATOR CHALLENGES Source text: ID:nPn67j9qba Further company coverage: CAT.N (( Reuters.Briefs@t
03-04 22:18
BRIEF-Caterpillar Transforms The Construction Worksite With Advanced Technology, Services And Solutions At Conexpo-Con/Agg 2026
BRIEF-Caterpillar Transforms The Construction Worksite With Advanced Technology, Services And Solutions At Conexpo-Con/Agg 2026 March 2 (Reuters) - Caterpillar Inc CAT.N : CATERPILLAR TRANSFORMS THE CONSTRUCTION WORKSITE WITH ADVANCED TECHNOLOGY, SERVICES AND SOLUTIONS AT CONEXPO-CON/AGG 2026 Source
03-02 22:07
ANALYSIS-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
ANALYSIS-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market Hims launches compounded pill at prices as low as $49 per month Analysts cite questions on efficacy, legality of pill Hims' move shifts focus from Novo's strong Wegovy pill launch Broader obesity market whipsawed a
02-07 02:10
Prestige Consumer Q3 revenue slightly beats expectations
Prestige Consumer Q3 revenue slightly beats expectations Overview Consumer healthcare firm's Q3 revenue slightly beat analyst expectations Adjusted EPS for Q3 met analyst expectations Company closed acquisition of Pillar5 Pharma and repurchased 0.8 mln shares Outlook Prestige narrows fiscal 2026 rev
02-05 19:10
UPDATE 2-Wegovy-maker Novo Nordisk warns of 'unprecedented' price pressure as shares tumble
UPDATE 2-Wegovy-maker Novo Nordisk warns of 'unprecedented' price pressure as shares tumble Novo forecasts profit and sales to fall as much as 13% in 2026 Analysts had expected 2% decline on average Novo competes with Eli Lilly in lucrative obesity drug market Market faces price pressures, rising co
02-04 15:16
Novo Nordisk's shock 2026 guidance points to obesity battle heating up
Novo Nordisk's shock 2026 guidance points to obesity battle heating up Novo forecasts profit and sales to fall as much as 13% in 2026 Analysts had expected 2% decline on average Novo competes with Eli Lilly in lucrative obesity drug market Market faces price pressures, rising competition By Maggie F
02-04 14:40
